General Hematology
Editorial: Prophylactic anticoagulation for patients in hospital with covid-19
23 Feb, 2021 | 01:59h | UTCProphylactic anticoagulation for patients in hospital with covid-19 – The BMJ
Related: Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials AND Cohort study: Early initiation of prophylactic anticoagulation linked to reduced mortality in patients admitted to hospital with Covid-19
COVID‐19 convalescent plasma: Interim recommendations from the AABB
19 Feb, 2021 | 02:56h | UTCCOVID‐19 convalescent plasma: interim recommendations from the AABB – Transfusion
News release: AABB panel issues interim recommendations for Covid-19 convalescent plasma use
M-A: The effect of convalescent plasma therapy on COVID-19 patient mortality
18 Feb, 2021 | 03:07h | UTCRelated study (not published yet) with conflicting results: RECOVERY trial: No Benefit from convalescent plasma in hospitalized patients with Covid-19 (news release and commentary)
COVID-19: A Hematologist’s Perspective
17 Feb, 2021 | 01:35h | UTCCoronavirus Disease 2019 (COVID-19): A Haematologist’s Perspective – Acta Haematologica
Editorial: A Haematologist’s Guide to Coronavirus Disease 2019: Encyclopaedia or Doorstop?
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
15 Feb, 2021 | 00:49h | UTC
Cohort study: Early initiation of prophylactic anticoagulation linked to reduced mortality in patients admitted to hospital with Covid-19
15 Feb, 2021 | 01:18h | UTCCommentaries: Preventive blood thinning drugs could reduce COVID hospital deaths – London School of Hygiene & Tropical Medicine AND Preventive blood thinning drugs linked to reduced risk of death in COVID-19 patients – The BMJ AND Expert reaction to a study looking at prophylactic anticoagulants as a treatment for hospitalised patients with COVID-19 – Science Media Centre AND
Commentary on Twitter
Blood thinning drugs are now linked to a reduced risk of death for COVID19 patients. Those given preventive blood thinners (prophylactic anticoagulants) within 24 hours of hospital admission for Covid were less likely to die. New report in the BMJ https://t.co/KQqQ3Zoj8B pic.twitter.com/6wJj8mEucw
— delthia ricks 🔬 (@DelthiaRicks) February 12, 2021
RCT: Among patients with acute MI and anemia, a restrictive transfusion strategy resulted in a noninferior rate of major cardiovascular events compared to a liberal transfusion strategy
10 Feb, 2021 | 01:39h | UTCEffect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial – JAMA (free for a limited period)
Commentary: Restrictive vs. Liberal Blood Transfusion Strategy for MI and Anemia – American College of Cardiology
Commentary on Twitter
Effect of Restrictive vs Liberal Blood Transfusion Strategy on Adults With Myocardial Infarction and Anemia https://t.co/PUtmUj0haw
— JAMA Cardiology (@JAMACardio) February 9, 2021
Thrombosis and COVID-19: Controversies and (Tentative) Conclusions
9 Feb, 2021 | 01:41h | UTCThrombosis and COVID-19: Controversies and (Tentative) Conclusions – Clinical Infectious Diseases
Commentary on Twitter
Excellent review of thrombosis and anticoagulation in #COVID19 by @connors_md and @RMKGandhi
Paradoxically, anticoagulation may be most beneficial in moderately ill patients with #COVID19, as the bleeding risk may be excessive in the critically ill https://t.co/75TiNs0iej pic.twitter.com/v0avzhFl3f
— John Ross (@JohnRossMD) February 6, 2021
Case report: SARS-CoV-2 evolution in immunocompromised patient treated with convalescent plasma
7 Feb, 2021 | 21:32h | UTCSARS-CoV-2 evolution during treatment of chronic infection – Nature
Commentary on Twitter
Just published @nature: The evolution of #SARSCoV2 in an immunocompromised patient, over > 100 days, that markedly accelerated once treated w/ convalescent plasma, with mutations that altered the response to neutralizing antibodies, by @GuptaR_lab https://t.co/SI4QL6BRXe pic.twitter.com/wqI1C2EYjQ
— Eric Topol (@EricTopol) February 5, 2021
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease
3 Feb, 2021 | 01:07h | UTCASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease – Blood
[Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
1 Feb, 2021 | 01:58h | UTCFull-Dose Heparin Best for Moderate COVID-19 Regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials – MedPage Today (free registration required)
Trial results: ATTACC, ACTIV-4a & REMAP-CAP multiplatform RCT Results of interim analysis – ATTACC Trial
Cohort study: Long-term clinical outcomes of hematopoietic stem cell transplantation in 210 patients with multiple sclerosis
25 Jan, 2021 | 01:15h | UTCLong-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis – Neurology (link to abstract – $ for full-text)